Meta-analysis of 13 retrospective studies (2271 patients) with advanced pancreatic cancer on nanoliposomal irinotecan: prior conventional irinotecan was associated with worse overall survival (adjusted HR 1.42, 95% CI 1.03–1.96) and PFS (adjusted HR 1.72).
Meta-analysisn = 2,271
Lee et al. Impact of prior conventional irinotecan use on nanoliposomal irinotecan efficacy in advanced pancreatic cancer: a meta-analysis